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Abolishes the Enzymatic Activity of Complex II in the Mitochondrial
Respiratory Chain and Activates the Hypoxia Pathway
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Hereditary paragangliomas are usually benign tumors of the autonomic nervous system that are composed of cells
derived from the primitive neural crest. Even though three genes (SDHD, SDHC, and SDHB), which encode three
protein subunits of cytochrome b of complex II in the mitochondrial respiratory chain, have been identified, the
molecular mechanisms leading to tumorigenesis are unknown. We studied a family in which the father and his
eldest son had bilateral neck paragangliomas, whereas the second son had a left carotid-body paraganglioma and
an ectopic mediastinal pheochromocytoma. A nonsense mutation (R22X) in the SDHD gene was found in these
three affected subjects. Loss of heterozygosity was observed for the maternal chromosome 11q21-q25 within the
tumor but not in peripheral leukocytes. Assessment of the activity of respiratory-chain enzymes showed a complete
and selective loss of complex II enzymatic activity in the inherited pheochromocytoma, that was not detected in
six sporadic pheochromocytomas. In situ hybridization and immunohistochemistry experiments showed a high
level of expression of markers of the angiogenic pathway. Real-time quantitative reverse transcriptase (RT)–PCR
measurements confirmed that vascular endothelial growth factor and endothelial PAS domain protein 1 mRNA
levels were significantly higher (three- and sixfold, respectively) than those observed in three sporadic benign
pheochromocytomas. Thus, inactivation of the SDHD gene in hereditary paraganglioma is associated with a com-
plete loss of mitochondrial complex II activity and with a high expression of angiogenic factors.
Introduction
Paragangliomas are highly vascularized benign tumors
derived from neuroectodermal cells. They are prefer-
entially localized in the carotid body. They may be as-
sociated with other neural-crest–derived tumors, such as
pheochromocytomas. In ∼30% of published cases, para-
gangliomas are inherited. Individuals with familial para-
gangliomas (MIM 168000, MIM 601650, and MIM
605373) have a more severe presentation (early age at
onset and tumors at multiple sites) than do those with
sporadic disease. Genetic linkage analyses in several
large families have identified loci associated with para-
ganglioma on 11q23 (PGL1; Heutink et al. 1992) and
11q13.1 (PGL2; Mariman et al. 1995). Transmission is
autosomal dominant with incomplete penetrance when
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transmitted through fathers, whereas no disease phe-
notype is observed if transmission is maternal, an ob-
servation consistent with maternal genomic imprinting.
The third, not maternally imprinted, susceptibility gene
was located in 1q21-q23 (PGL3) in one German family
(Niemann et al. 1999). It has recently been demonstrated
that PGL1 corresponds to the SDHD gene, which en-
codes a mitochondrial respiratory-chain protein of com-
plex II called “cybS” (small subunit of cytochrome b in
succinate-ubiquinone oxidoreductase) (Baysal et al.
2000). In addition to five nonsense mutations, the au-
thors reported a loss of the maternal allele in tumor
DNA, suggesting that SDHD is a tumor-suppressor gene
that requires two events for inactivation, as hypothesized
by Knudson (1986). Then, several germline SDHD mu-
tations were reported in families with paraganglioma
(Badenhop et al. 2001; Milunsky et al. 2001) and in
families with pheochromocytoma (Astuti et al. 2001a).
The SDHC gene encoding the large subunit of cyto-
chrome b in succinate-ubiquinone oxidoreductase was
reported to correspond to the PGL3 gene (Niemann and
Mu¨ller 2000; Niemann et al. 2001). More recently, in-
activating SDHB gene mutations were also detected in
two kindreds (Astuti et al. 2001b).
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Figure 1 Analysis of mutations in the SDHD gene. A, Schematic
representation of the affected kindred. Paragangliomas are represented
by a hatched box and pheochromocytoma by a blackened box. B,
Sequence analysis of exon 2 of SDHD in DNA extracted from the
peripheral blood of one affected subject (II:2) and from an unaffected
relative (I:2). C, Amplification of exon 2 from the blood of all family
members and its cleavage with BstBI. The BstBI restriction fragments,
obtained after digestion at 65C for 3 h, were separated by electro-
phoresis on a 3% agarose gel. The normal maternal allele gave two
bands after enzymatic digestion (159 and 131 bp), whereas the paternal
mutated allele gave a single undigested band (290 bp). A three-band
heterozygous pattern (290, 159, and 131 bp) was observed for patients
I:1, II:1, and II:2, whereas the unaffected subjects (I:2, III:1 and III:2)
exhibit a two-band homozygous profile. ND p not digested.
Complex II or succinate-ubiquinone reductase (EC
1.3.99.1) is an important enzymatic complex crucial for
both the tricarboxylic acid cycle and the aerobic res-
piratory chains of mitochondria (Saraste 1999). It con-
tains succinate dehydrogenase, with subunits that en-
able this enzyme to bind directly to the inner
mitochondrial membrane. These four nuclear-encoded
subunits are composed of two hydrophilic proteins—a
flavoprotein (SDHA [70 kD]) and an iron-sulfur protein
(SDHB [27 kD]) that form the enzymatic core of the
complex—and two hydrophobic integral membrane
protein subunits—the large (cybL or SDHC [15 kD])
and small (cybS or SDHD [12 kD]) subunits of cyto-
chrome b that anchor the complex. Mitochondria can
act as O2 sensors by increasing the generation of reactive
oxygen species, which are required for hypoxia-induc-
ible factor 1 DNA–binding activity and subsequent in-
creases in the synthesis of mRNA that encodes eryth-
ropoietin, vascular endothelial growth factor (VEGF),
and glycolytic enzymes (Chandel et al. 1998). Because
the carotid body contains O2 chemoreceptors, it has
been suggested that chronic hypoxic stimulation could
account for the high frequency of sporadic occurrence
carotid-body paragangliomas in individuals who live at
high altitudes (Pacheco-Ojeda et al. 1988) and for the
involvement of the SDHD protein in the pathogenesis
of hereditary paraganglioma (Baysal et al. 2000).
In the present study, we investigated the function of
a new nonsense mutation in the SDHD gene discovered
in a family with familial paraganglioma. We used mo-
lecular genetics at the germline and somatic levels and
in vitro measures of enzymatic activity of the mito-
chondrial respiratory chain to determine the nature of
the genetic defect and to assay its effects on the activity
of complex II. We have performed in situ hybridization,
immunohistochemistry, and real-time quantitative RT-
PCR to evaluate the expression of genes involved in the
angiogenic pathway in tumoral tissues.
Subjects and Methods
Patients
Genetic counseling was offered to a French family that
had a history of hereditary paraganglioma. The pedigree
of this family is presented in figure 1A. Subject I:1 un-
derwent surgery for bilateral carotid-body tumors. His
wife (subject I:2) was unaffected by tumors. The first
son (subject II:1) had bilateral neck paragangliomas, and
the second (subject II:2) had a unilateral glomus tumor
with an ectopic mediastinal pheochromocytoma. Clini-
cal examination of the second son’s two children (sub-
jects III:1 and III:2) revealed no signs of tumor. Written
informed consent was obtained before blood samples
were drawn for DNA analysis of each affected and un-
affected subject.
Somatic and Constitutive DNA Analysis
DNA was extracted from leukocytes by the classical
phenol/chloroform extraction protocol. After removal
by surgery, the unfixed ectopic pheochromocytoma from
subject II:2 was immediately frozen by immersion in liq-
uid nitrogen. DNA from pheochromocytoma material
was extracted using a commercially available kit (RNA/
DNA System, Qiagen). The four exons of the SDHD
gene (GenBank accession number AB 026906) were am-
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plified by PCR with primers and a procedure that has
been described elsewhere (Baysal et al. 2000). PCR re-
actions were performed with 3 mM MgCl2 and 0.1 U
TaqGold DNA polymerase (Applied Biosystems). The
resulting PCR products were directly sequenced using
an ABI 3700 fluorescence sequencer (Applied Biosys-
tems). Genotyping of the R22X mutation within the
family was performed by forward and reverse sequenc-
ing using 2F6610, 5′-CCCCAGTGAAATAGATGCT-
ATC-3′ (forward) and 5′-AGCAGCAGCGATGGAGA-
GAA-3′ (reverse) primers. The R22X mutation was
confirmed by BstBI restriction-enzyme digestion at 65C
for 3 h. The digested amplicons were visualized after
electrophoresis in a 3% ethidium bromide–stained aga-
rose gel. The undigested amplicon size was 290 bp; the
wild-type allele digested byBstBI yielded two bands (159
and 131 bp).
We investigated whether the PGL1 locus cosegre-
gated with the disease, using a set of seven fluorescent
polymorphic microsatellite 11q markers (D11S987,
D11S1314, D11S901, D11S937, D11S4175, D11S898,
and D11S908) provided by the ABI Prism Linkage Map-
ping Set, version 2 (Applied Biosystems). These markers
overlap a 10-cM region between 11q13 (PGL2 locus)
and 11q23 (PGL1 locus). Loss of heterozygosity
(LOH) at the PGL1 locus was investigated with a
second set of fluorescent oligonucleotides (D11S1339,
D11S1343, D11S5011, D11S5019, D11S1347,
D11S908, D11S4111, D11S4104, D11S925, D11S934,
D11S4131, D11S4125, and D11S968) (Life Technolo-
gies). Amplification conditions were as follows: initial
denaturation at 95C for 10 min, then 35 cycles with 1
min of denaturation at 95C, 1 min of annealing at 55C,
and 1 min of extension at 72C, followed by a final
extension at 72C for 30 min. The amplicons were sub-
jected to electrophoresis and were analyzed with an ABI
3700 instrument.
Enzyme Assays
The activities of succinate cytochrome c reductase
(SCCR) were measured spectrophometrically in tissue
homogenates. After we had checked for the absence of
germline and somatic mutation of the SDHD gene, ex-
periments were performed using six sporadic pheo-
chromocytomas as controls. The activity of the respi-
ratory-chain complexes was measured, as described
elsewhere (Rustin et al. 1994). SSCR, reflecting the com-
bined activity of complexes II and III, was measured in
medium A, which consists of 10 mM phosphate buffer
(pH 7.8), 10 mM succinate, 1 mg/ml bovine serum al-
bumin, 3 mM rotenone (to avoid oxaloacetate produc-
tion by the malate dehydrogenase, an activity that de-
pends on the recycling of reduced nicotinamide adenine
dinucleotide by the respiratory chain), 200 mM adeno-
sine triphosphate, to fully activate the succinate dehy-
drogenase; and 1 mM potassium cyanide, to avoid cy-
tochrome c reoxydation by the cytochrome c oxidase.
The addition of 40 mM oxidized cytochrome c started
the reaction. Isolated complex II (EC 1.3.5.1) was mea-
sured as the succinate quinone dichlorophenol indo-
phenol (DCPIP) in 1 ml of medium A added with 1 mM
DCPIP, and the reaction was started by adding 50 mM
decylubiquinone. Under these conditions, electron flow
from succinate to quinone requires the functional and
structural integrity of the four subunits (A–D) of com-
plex II. The activity of SDH itself (subunit A plus B) was
measured by substituting 800 mM phenazine methosul-
fate (PMS) to decylubiquinone in the presence of 1 mM
thenoyltrifluoroacetone, which inhibits electron flow
from subunit C to the quinone-acceptor site of complex
II. Under these conditions, electron flow from succinate
to PMS needs only the functional integrity of subunits
A and B of the succinate dehydrogenase (EC 1.3.99.1).
Immunohistochemistry and In Situ Hybridization
Carotid-body paragangliomas (subjects I:1 and II:2)
and the ectopic pheochromocytoma (subject II:2) were
fixed in formalin and embedded in paraffin. Sections
(5–7 mm) were cut and mounted on silane-coated slides.
In situ hybridization was performed, as described else-
where (Sibony et al. 1995), using [35S]-labeled ribo-
probes produced by in vitro transcription of the follow-
ing cDNA fragments inserted into pCRII: endothelial
PAS domain protein (EPAS) 1 (nucleotides [nt]
512–985), VEGF (nt 1–576), VEGFR-1 (nt 1–1610),
VEGFR-2 (nt 57–1387), and Tie2 (nt 52–975). Immu-
nohistochemistry experiments were performed, as de-
scribed elsewhere (Favier et al. 1999), using an antity-
rosine hydroxylase antibody (Institut Jacques Boye) at
a dilution of 1:1,500, a specific antineurone enolase an-
tibody used at a dilution of 1:1,000 (gift of N. Lamande´)
(Legault-Demare et al. 1981) and an anti-HIF1a anti-
body used at a dilution of 1:1,000 (gift from D. Richard
and J. Pouyssegur) (Richard et al. 2000).
Real-Time Quantitative RT-PCR
Total RNA of frozen inherited pheochromocytoma of
subject II:2 and of three sporadic pheochromocytomas
were extracted with the RNeasy kit (Qiagen), followed
by RNAse-free DNAse treatment. The three sporadic
pheochromocytomas were used as controls. Direct se-
quencing of DNA extracted from these tumors showed
no SDHD mutation, and enzyme assays showed normal
SSCR activities. Reverse transcription of 1 mg total RNA
was performed in a total volume of 50 ml with 3 mmol/
liter MgCl2, 2.5 mmol/liter dNTP mix, 75 mmol/liter
KCl, 50 mmol/liter Tris-HCl (pH 8.3), 8.3 mmol/liter
DTT, 2.5 mmol/liter random hexamer, 1 U/ml RNAsin,
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Figure 2 Loss of maternal allele at the SDHD gene. A, Electro-
phoretograms corresponding to the forward (a) and reverse (b) se-
quences of exon 2 of SDHD from the pheochromocytoma of subject
II:2. The small peak of C probably results from minor contamination
from nontumoral DNA (blood vessel and/or leukocytes). B, Amplifi-
cation of exon 2 and cleavage with BstBI: undigested control (lane a),
digested profiles of maternal peripheral DNA (lane b), germline DNA
(lane c), and pheochromocytoma DNA (lane d) of subject II:2. The
normal maternal allele shows two bands (159 and 131 bp) after di-
gestion and the undigested paternal mutated allele shows one band
(290 bp).
and 400 U Moloney murine leukemia virus (MMLV)
RT. Samples were incubated at 65C for 15 min, 37C
for 1 h, and 99C for 3 min. Quantitation of EPAS1 and
VEGF cDNAs was performed with a SYBR Green assay,
using an ABI Prism 7700 sequence detector (Applied
Biosystems). Quantitation of b-actin and 18S ribosomal
RNA control cDNAs was also performed with a real-
time TaqMan PCR assay. For amplification of EPAS1
(GenBank accession number NM 001430), primer se-
quences are 5′-GCGCTAGACTCCGAGAACAT-3′
(forward) and 5′-TGGCCACTTACTACCTGACCCTT-
3′ (reverse). For amplification of VEGF (GenBank ac-
cession number NM 003376), primer sequences are
5′-CTACCTCCACCATGCCAAGTG-3′ (forward) and
5′-TGATTCTGCCCTCCTCCTTCT-3′ (reverse). For
amplification of b-actin and 18S ribosomal RNA prod-
ucts, primers and probe were purchased directly from
Applied Biosystems. Thermocycling conditions were 2
min at 50C and 10 min of initial denaturation at 95C,
which was followed by 45 cycles of two-step PCR that
consisted of 15 s at 95C and 1 min at 60C. Duplicate
experiments were performed to compare five dilutions
(1, 101, 102, 103, and 104) of each target cDNA
(EPAS1 or VEGF) and five dilutions (1, 101, 102, 103,
and 104) of each endogenous control (b-actin or 18S
ribosomal RNA) for the inherited pheochromocytoma
and the three sporadic pheochromocytomas. Relative
quantitation of EPAS1 and VEGF gene expression was
analyzed as a target-to-control expression ratio, using
the standard curve method (Higuchi et al, 1993). The
statistical significance of the differential expression be-
tween inherited and sporadic pheochromocytomas was
assessed by a Mann-Whitney nonparametric test (Sta-
view 5.0., SAS Institute).
Results
Clinical Features of the Family
In this family, tumors were transmitted through the
paternal line (fig. 1A). The father developed bilateral
neck paragangliomas in his sixties. Glomus carotid tu-
mors were diagnosed in his two sons when they were
!40 years of age. The clinical history of subject II:2 is
remarkable. He underwent surgery in 1998 to remove
a left-carotid–body paraganglioma, which was suspected
on the basis of self-examination and confirmed by ca-
rotid angiogram. Six months after surgery, a blood pres-
sure increase (to 150/100 mm Hg) was observed, to-
gether with a fivefold increase in urinary metanephrines
(19.4 nmol/24 h). Abdominal computed tomography
and whole-body scintigraphy with metaiodobenzyl gua-
nidine detected no tumor. An ectopic pheochromocy-
toma, 50 mm in diameter, was finally located in the
mediastinum behind the heart by octreotide scintigraphy
and thoracic computed tomography scan. This corre-
sponded to a 29-g catecholamine-secreting mediastinal
paraganglioma, which was surgically removed and had
not recurred after 18 mo of follow-up.
Germline and Somatic Analysis of the SDHD Locus
Linkage analysis showed a complete father-to-son pa-
ternal allele transmission for the seven markers of the
chromosome 11q13-q23 region, with no recombination
event. Direct sequencing of the four exons of the SDHD
gene from peripheral DNA of affected subjects showed
a CrT nt change in exon 2, creating a premature stop
codon in the sequence encoding the signal peptide
(R22X) of the mature protein (fig. 1B). This heterozy-
gous mutation which was confirmed by BstBI restriction
enzymatic digestion (fig. 1C), cosegregated with the
disease and was not found in 178 normal control
chromosomes.
DNA was extracted from the ectopic pheochromo-
cytoma tissue and the SDHD gene sequenced. Within
the tumor, a loss of the maternal allele was observed for
exon 2 of the SDHD gene (fig. 2A). The deletion of the
maternal allele was confirmed by the amplification of
exon 2 and its digestion by BstBI. Conversely, biallelic
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Figure 3 Loss of maternal allele at chromosome 11q21-25. The
LOH was typed by microsatellite analysis, using constitutive and tu-
mor DNA from patient II:2. The positions of the markers tested are
indicated on an ideogram of chromosome 11. The maternal allele lost
is indicated by a line and homozygosity by NI. * p noninformative
marker.
expression was observed in leukocytes. In tumor DNA,
the maternal allele was lost (fig. 2B). To determine the
extent of the LOH, 13 regional markers were genotyped
in the peripheral and tumor DNA of patient II:2 and
were compared with maternal and paternal peripheral
DNA (fig. 3). Ten of these markers were informative.
An LOH was observed between markers D11S1343 and
D11S968, demonstrating a terminal deletion 11q21-q25
of the maternal chromosome
Enzyme-Function Studies
We assessed the activity of respiratory-chain enzymes
in the pheochromocytoma developed by subject II:2 and
in six sporadic pheochromocytomas that were removed
and conserved in the same conditions and for which no
mutation of the SDHD gene was found. SCCR activity
(complex II plus III) was first measured in the control
pheochromocytomas (fig. 4A). Cytochrome c was re-
duced by succinate, and this reduction was readily in-
hibited by malonate, a competitive inhibitor of succinate
dehydrogenase (fig. 4C). After the addition of lauryl mal-
toside that increases the accessibility of duroquinol and
cytochrome c to complex III, the addition of duroquinol
triggered a rapid reduction of cytochrome c. This re-
duction was essentially inhibited by antimycin, making
it possible to estimate complex III activity (QCCR: an-
timycin-sensitive quinol cytochrome c reductase activity
or complex III) in the analyzed sample. Similar mea-
surements were made for the pheochromocytoma sam-
ple from subject II:2, which showed a complete loss of
SCCR activity and an increase in complex III activity
(fig. 4A). This resulted in the QCCR:SCCR ratio 500
times higher than that for the control pheochromocy-
tomas (fig. 4A). Cytochrome oxidase activity was nor-
mal in all samples analyzed (data not shown).
We then measured the activity of isolated complex II
(SQDR) by using quinone as an electron acceptor, in the
presence of cyanide. This activity was abolished in the
pheochromocytoma sample from subject II:2 but was
detected in control pheochromocytomas (fig. 4B). Fi-
nally, succinate dehydrogenase activity (SPDR) was mea-
sured by following the reduction of phenazine metho-
sulfate (PMSF) by succinate in the presence of
thenoyltrifluoroacetone, which blocks electron transfer
between the SDH (subunits A plus B) and the respiratory
chain. It was also undetectable in the pheochromocy-
toma sample from subject II:2 (fig. 4B). These results
demonstrate that this inactivating mutation of the
SDHD gene in patients with paraganglioma is associated
with the complete and selective loss of complex II elec-
tron transfer activity and with the loss of the succinate
dehydrogenase–mediated step of the Krebs cycle. This
complete loss of activity is consistent with somatic loss
of the wild-type maternal allele.
Gene Expression Studies
Because the oxidation of mitochondrial cytochromes
is known to be a sensor of hypoxia in the glomus carotid
body and in cells in general, we thought that complex
II mitochondrial chain inactivation might change the ex-
pression of genes sensitive to hypoxia and/or encoding
angiogenic factors in paragangliomas. The expression of
eight genes was studied using in situ hybridization and
immunohistochemistry (table 1) in carotid-body para-
ganglioma (fig. 5) and in pheochromocytoma from sub-
ject II:2 (fig. 6). We detected mRNA encoding the tran-
scription factor EPAS1 (HIF2a) (fig. 5A) in vascular
endothelial cells and also in vascular smooth muscle
cells. We observed very large amounts of this transcript
within the cell clusters characteristic of paragangliomas
(“Zellballen”), in chief cells (type I) of all specimens.
Immunostaining with a polyclonal antibody revealed
that its homolog, HIF1a, was also detected in these cells
(fig. 5B). Several putative target genes of these tran-
scription factors were also highly expressed in these
tissues. A very strong immunoreactivity was observed
for the neurone-specific enolase (NSE), which revealed
the Zellballen architecture (fig. 5D and 5I) of all para-
gangliomas, as well as in the cells of the pheochromo-
cytoma. This result was expected, because NSE is con-
sidered an indicator of neuroendocrine differentiation
(Schmechel et al. 1978). The tyrosine hydroxylase (TH)
protein was also detected in these cells in all paragan-
gliomas (fig. 5C) and was particularly strong in the pheo-
chromocytoma. We observed a high expression of the
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Figure 4 Mitochondrial enzyme function studies. A, Spectrophotometric assay of respiratory-chain enzyme activities in tumors with (first
trace) and without (second trace) mutations in SDHD. The values given on the traces are nmol/min/mg protein. Mean  1 SD is indicated in
brackets. LMp lauryl maltoside; DUQH2p decylubiquinol. B, Enzyme activities in subject II:2 (inherited pheo) and controls (sporadic pheos).
SCCRpmalonate-sensitive succinate cytochrome c reductase activity (complexes IIIII). SQDRp succinate quinone dichlorophenolindophenol
reductase (complex II). SPDRp succinate phenazine methosulfate dichlorophenolindophenol reductase (succinate dehydrogenase).C, Schematic
representation of the principal electron paths through the various subunits of complex II. The acceptor sites for quinones and phenazine
methosulfate are indicated as well as the thenoyltrifluoroacetone inhibition site. Aa p antimycin; C p SDHC; CIII p complex III; CIV p
complex IV; Dp SDHD; DCPIPp dichlorophenolindophenol; DUQp decylubiquinone; DUQH2p decylubiquinol; FADp flavine adenosine;
Fp p flavoprotein; Ip p iron protein; KCN p potassium cyanide; PMS p phenazine methosulfate; Q p ubiquinone; Q

p semiubiquinol;
QH2 p ubiquinol. Q, Q
, and QH2 are the various forms of the ubiquinone present in the mitochondrial membrane.
VEGF gene in chief cells (fig. 5E and 5J) and of that
encoding its receptor, VEGF-R1 (fig. 5F and 5K) in en-
dothelial cells from large vessels and capillaries sur-
rounding the Zellballen structures (fig. 5K). Higher levels
of VEGF-R1 than of VEGF-R2 were detected (fig. 5G),
particularly in large blood vessels, in which VEGF-R2
was hardly detectable. The Tie2 receptor hybridization
signal was at the threshold of detection in vascular en-
dothelial cells (fig. 5H).
Interestingly on in situ hybridization experiments, the
level of expression of VEGF and of EPAS1 mRNA (fig.
6) was higher in the three carotid-body paragangliomas
and in the pheochromocytoma of the family in the pre-
sent study than those observed in sporadic benign pheo-
chromocytomas. To confirm these observations, we used
real-time quantitative RT-PCR to compare the level of
EPAS1 and VEGF transcripts in pheochromocytoma
from subject II:2 and three sporadic pheochromocyto-
ma controls who had no SDHD mutation and a normal
SDH activity. As indicated in figure 7, there was, on
average, a sixfold increase in the level of EPAS1 mRNAs
and a threefold increase of VEGF mRNAs whatever the
endogenous RNA control used. The statistical signifi-
cance of these results was demonstrated using a Mann-
Whitney statistical test: , for allzp 2.910 Pp .0036
combinations (EPAS1 vs. b-actin, EPAS1 vs. 18S, VEGF
vs. b-actin, and VEGF vs. 18S).
Discussion
The mitochondrial respiratory chain is a protein com-
plex of potential interest in oncogenesis, especially after
the discovery that the SDHD gene corresponds to the
PGL1 locus (Baysal et al. 2000). The present study not
only confirms the role of the SDHD gene in hereditary
paraganglioma but also shows that the induced defect
in the complex II mitochondrial chain is associated with
the overproduction of angiogenic factors, which may in
turn stimulate angiogenesis and therefore tumor growth.
Three different loci have been implicated in familial
paraganglioma. The inheritance pattern of these genes
is usually consistent with autosomal dominant trans-
mission with maternal genomic imprinting (Van der
Mey et al. 1989). Indeed, the children of affected fathers
developed tumors, whereas the children of affected
mothers remained tumor free. Several authors have sug-
gested that an epigenetic modification, such as the meth-
ylation of CpG islets on parental chromosomes might
confer a reversible difference on the maternal and pa-
ternal chromosomes during gametogenesis (Van der
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Table 1
Semiquantitative Assessment of In Situ Hybridization and Immunohistochemistry Observations
SUBJECT AND TUMOR
IN SITU HYBRIDIZATION IMMUNOHISTOCHEMISTRY
EPAS1 VEGF VEGF-R1 VEGF-R2 Tie2 HIF1a NSE TH
I:1
Right paraganglioma        
Left paraganglioma        
II:2
Paraganglioma        
Pheochromocytoma        
NOTE.—Relative intensities of the markers studied are represented for the three carotid-body paragangliomas
(in subjects I:1 and II:2) and the pheochromocytoma (in subject II:2). Labeling intensity was evaluated twice
in a blinded manner and was graded using a 5-scale system:p no signal;pweak;pmoderate;
p strong;  p very strong.
Mey et al. 1989; Milunsky et al. 1997). This modifi-
cation could affect a tissue-specific promoter (Pfeifer,
2000). This hypothesis is consistent with biallelic ex-
pression of the SDHD gene in tumor tissue. Nonethe-
less, our data provide no evidence for maternal imprint-
ing but instead suggest an LOH in tumor tissue,
consistent with Knudson’s classical two-hit hypothesis
for the induction of tumor formation (Knudson 1986).
Conversely, we were able to detect biallelic expression
of the SDHD gene and normal complex II activity in
adrenal tissue in two other sporadic pheochromocyto-
mas (data not shown).
Tumor prognosis probably differs with the function
and number of deleted genes. A high frequency of 11q
loss in familial paragangliomas, similar to the loss in
the family described here, was recently reported else-
where (Dannenberg et al. 2001). Several of the genes
surrounding SDHD on human chromosome 11q21-
q25, may be involved in tumorigenesis (Koreth et al.
1999; Baysal et al. 2001). One of them is the PPP2R1B
gene which is separated from SDHD by only 250 kb
on the physical map. This putative tumor-suppressor
gene, which encodes the b isoform of the A subunit of
serine/threonine protein phosphatase 2A, has been im-
plicated in human lung and colon cancer (Wang et al.
1998). Therefore, it will be important to study the phe-
notype-genotype relationships in several families with
paraganglioma to determine whether the size and lo-
cation of the somatic deletions are associated with a
higher risk of malignancy in paraganglioma and spo-
radic pheochromocytoma induced by SDHD mutations
(Gimm et al. 2000).
It has been suggested that mitochondria are the pri-
mary site of oxygen sensing in the carotid body (Prab-
hakar. 2000). Mitochondria produce cellular energy by
a process of oxidative phosphorylation involving five
respiratory-enzyme complexes. Complex II transfers
electrons from succinate to the ubiquinone pool. Iso-
lated complex II deficiency has been reported in Leigh
syndrome. The causative mutation was identified in the
SDHA gene encoding the flavoprotein of complex II,
and the enzymatic defect was partial (Bourgeron et al.
1995). No associated tumor was detected in this family
(A.R. and P.R., unpublished data). In Caenorhabditis
elegans, a mutant of mev-1 gene that is homologous to
the human SDHC gene has been found to be hypersen-
sitive to high oxygen concentrations. In mev-1 mutant
animals, the ability of complex II to catalyze electron
transport from succinate to ubiquinone is compromised,
indirectly causing an increase in superoxide levels and
premature aging (Ishii et al. 1998). Surprisingly enough,
succinate dehydrogenase (subunits A and B), assumed
to be not inserted in the mitochondrial membrane, was
found still active despite the loss of the anchoring sub-
units in mev-1 mutant animals. These observations con-
trast with numerous cases where the absence (or even
the mutation) of one subunit in a given respiratory-
chain complex results in the destabilization of the com-
plex and the subsequent proteolysis of the noninserted
subunits (Birch-Machin et al. 1996; Bruno et al. 1999;
Clark et al. 1999). Our studies of human pheochrom-
ocytomas did not confirm the observation made in the
nematode. The defect in one of the anchoring subunits
is predicted to result in the noninsertion of the SDH
and presumably to its proteolysis. Accordingly, muta-
tion in the SDHD gene of subject II:2 resulted in the
complete loss of both the catalytic activity of succinate
dehydrogenase (subunits A plus B) and electron flow
from succinate to the ubiquinone pool, which requires
all complex II subunits. The complete abolition of com-
plex II activity resulting from a heterozygous consti-
tutive mutation of the SDHD gene associated with a
somatic maternal LOH, as described in the pheochrom-
ocytoma of this family, has not been reported before.
This dramatic disturbance of the mitochondria res-
piratory chain accounts for the hypoxic status of the
cells and probably explains the high level of expression
of genes encoding hypoxia induced factors. Jyung et al.
(2000) reported the detection of positive immunohis-
tochemical staining for VEGF in 65% of sporadic glo-
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Figure 5 Gene-expression patterns in right carotid-body paraganglioma of patient I:1, as shown by in situ hybridization or immunostaining.
EPAS1 mRNA is observed in both endothelial cells and tumor cells (A). The protein of the homolog transcription factor HIF1a is also present
(B). Tyrosine hydroxylase (C), NSE (D and I) and VEGF (E and J) are present at a very high level in tumor cells within the Zellballen clusters,
whereas VEGF receptors R1 (F and K) and R2 (G) transcripts are restricted to endothelial cells. Note the absence of VEGF-R2 in the wall of
the central large vessel (*) and the almost undetectable signal with the Tie2 probe (H). High magnifications clearly reveal the expression of
NSE (I) and VEGF (J) within the Zellballen structures (arrowheads), surrounded by a VEGF-R1 positive capillary network (K, arrows). The
in situ hybridization signals are visualized either under dark (A and E–H; signal visible as white dots) or bright field illumination (J andK;labeling
detected by black dots). Immunostaining (B, D, and I) is revealed by a brown coloration. Scale bars p 200 mm (A–H); scale bars p 100 mm
(I–K).
mus paraganglioma studied. We have confirmed and
extended these results in inherited paragangliomas by
describing the expression pattern of several angiogenic
markers that may be involved in tissue adaptation to
hypoxia. We have shown, in these tumors, the strong
expression of hypoxia-inducible transcription factors
(EPAS1/HIF2a and HIF1a) and genes encoding some
of the targets of these factors. The hybridization signal
for EPAS1 and for VEGF and its receptor VEGF-R1
was particularly strong in these tumors. We made two
important observations that suggest a direct link be-
tween the high expression of genes encoding angiogenic
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Figure 6 EPAS1 mRNA expression; comparison between patient II:2 pheochromocytoma and a sporadic benign pheochromocytoma. The
expression of EPAS1 within tumor cells is higher in the inherited pheochromocytoma (A and B) than in a sporadic pheochromocytoma (C and
D). In contrast, the intensity of EPAS1 signal does not vary between the two samples in endothelial cells (black arrows). The in situ hybridization
signals are observed under dark-field illumination for low magnifications (A and C [white dots]) and under bright field illumination for
enlargements (B, D [black dots]). White arrows p blood vessels;  p very strong signal;  p weak signal. Scale bars p 100 mm.
factors and the loss of SDHD function. First, VEGF-R1
mRNA, which encodes the VEGF receptor induced in
hypoxic conditions (Gerber et al. 1997), was found to
be more abundant than VEGF-R2 mRNA. Second, the
level of EPAS1 and VEGF labeling observed in the three
paraganglioma tumors and in the pheochromocytoma
of this family was stronger than that observed in spo-
radic benign pheochromocytomas. These observations
were confirmed by quantitative RT-PCR experiments
which revealed a higher expression of both genes in
patient II:2 pheochromocytoma than in three sporadic
pheochromocytomas, with no SDHD mutation and a
normal SDH activity. The mutation in the SDHD gene
is therefore probably involved in induction of the hy-
poxia/angiogenesis response and possibly in tumor de-
velopment. However, it is unclear whether the activation
of hypoxia pathways is or is not sufficient to induce
tumorigenesis by itself. It remains possible that other
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Figure 7 Real-time quantitative RT-PCR experiments. The level of EPAS1 and VEGF transcripts were compared between the SDHD
mutated pheochromocytoma (inherited Pheo) with three sporadic pheochromocytomas (sporadic Pheo 1, 2, and 3). Comparison of quantitative
DNA data obtained with EPAS1 as target and b-actin (A) or 18S ribosomal RNA (B) as endogenous control and of data obtained with VEGF
as target and b-actin (C) or 18S ribosomal RNA (D) as endogenous controls. The circle represents the mean of 10 calculated measurements
(ratio of target gene on reference gene for each of five log of concentration in duplicate). The superior bar shows the maximal value, and the
inferior bar shows the minimal value.
functions, downstream from SDHD, are impaired in
these cells and/or that genes other than SDHD are also
affected (e.g., PPP2R1B).
Recent identification of mutations in the SDHD,
SDHC and SDHB genes as responsible for familial par-
aganglioma has added to the molecular tools available
for genetic counseling, which was previously based on
indirect testing using microsatellite markers from chro-
mosome 11q13 and 11q23 (Oosterwijk et al. 1996; Bik-
hazi et al. 1999; Petropoulos et al. 2000). Genetic di-
agnosis can now be made by direct sequencing to search
for a causative mutation in these three genes, even in
families with few affected members. The discovery of a
genomic mutation in a patient with paraganglioma is
important for the genetic counseling of his or her family,
including predictive DNA testing mutations in all rel-
atives and screening for paraganglioma at a presymp-
tomatic stage. Indeed, the early detection of paragan-
glioma reduces the incidence of morbidity and mortality
(Petropoulos et al. 2000).
In conclusion, this study shows that somatic loss of
maternal allele of the PGL1 locus, together with in-
herited paternal mutation of the SDHD gene, is re-
sponsible for a complete loss of activity of the complex
II of the mitochondrial respiratory chain and is asso-
ciated with a stimulation of angiogenic factors that
might in turn facilitate or trigger tumorigenesis in para-
ganglial tissues.
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